Multivesicular Liposome Stability via Nested Phospholipid Architecture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposomal systems for delivering cytotoxic drugs and biomolecules face challenges with stability and controlled release, as they are prone to dissipation due to weakly associated lipids, leading to inefficient delivery and uptake by disease state cells and tissues.
Innovation Solution
The development of multivesicular liposomes with a carrier liposome particle encapsulating sub-chamber liposome nanoparticles, where the carrier phospholipid bilayer has a larger tail group than the sub-chamber phospholipid bilayer, stabilized by crosslinking and PEG functionalization, allowing for controlled release and enhanced encapsulation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If liposomal carriers are formed by bilayers of phospholipids with weakly associated lipids, then the system is simple and easy to manufacture, but the liposomes dissipate before complete circulation leading to poor stability
Solution Approach 1:
The patent employs a multivesicular liposome structure where multiple smaller internal vesicles (200-500 nm) are nested within a larger external vesicle (1-5 μm). This nested architecture provides structural stability and prevents dissipation during circulation, as the multiple vesicles work together to maintain integrity while delivering therapeutic payloads to target cells.
2Reliability
If liposomal carriers are used for delivery of cytotoxic drugs and biomolecules, then the delivery capacity is improved, but the liposomes are prone to dissipation leading to inefficient delivery
Solution Approach 1:
The nested multivesicular structure with multiple internal vesicles provides enhanced stability and prevents dissipation during circulation, ensuring reliable delivery of cytotoxic drugs and biomolecules to target cells while maintaining high delivery efficiency.
Solution Approach 2:
The patent utilizes changes in salt concentration between the smaller internal vesicle compartments and the larger external vesicle to control the release of biologically active therapeutics. This parameter change triggers controlled release at the target site, improving delivery reliability.
3Quantity of substance
If conventional liposomal systems are used, then the encapsulation process is simple, but the encapsulation efficiency is low due to dissipation before complete circulation
Solution Approach 1:
The multivesicular liposome structure with multiple nested vesicles significantly improves encapsulation efficiency by providing multiple compartments for loading therapeutic payloads. The nested architecture prevents dissipation and maintains high quantity of encapsulated substances throughout circulation.
Solution Approach 2:
The patent divides the liposomal carrier into multiple segmented vesicles (internal and external compartments) that can independently encapsulate different therapeutic agents. This segmentation increases overall encapsulation capacity and efficiency while maintaining system stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a stable and efficient delivery system that maintains therapeutic payloads for extended periods, achieving high encapsulation efficiencies and controlled release kinetics, effectively targeting disease state cells and tissues.
Implementation Method 1
stabilized by crosslinking and PEG functionalization
Implementation Method 2
stabilized by crosslinking and PEG functionalization
Data Source
AI summary
A multivesicular liposome composition includes a plurality of multivesicular liposomes. Each multivesicular liposome includes a carrier liposome particle including carrier phospholipid bilayer and having an average diameter less than 1 micron; and at least one sub-chamber liposome nanoparticle including a sub-chamber liposome nanoparticle bilayer and having an average diameter less than about 50 nm. The carrier liposome particle encapsulates the at least one sub-chamber liposome nanoparticle. Characteristically, tail groups of the carrier liposome phospholipids are larger than tail groups phospholipids of the at least one sub-chamber liposome nanoparticle.